论文部分内容阅读
目的:探讨芬吗通在人流不全患者中应用的临床疗效及安全性。方法:将2011年1月~2014年1月该院人流不全患者分成两类:一类为芬吗通治疗组;另一类为米非司酮加缩宫素治疗组。再在芬吗通组中随机抽取50例作为观察组,同法在米非司酮和缩宫素组中抽取50例作为对照组,对比两组在阴道出血时间、转经时间、治愈情况及药物不良反应方面的差异。结果:观察组在阴道出血时间、转经时间、治愈效果方面均优于对照组,药物不良反应两组则无统计学差异。结论:用芬吗通治疗人流不全(B超提示宫腔异常回声最大径<30mm)方面,可以最大程度减少再次清宫,促进子宫及月经恢复,值得推广。
Objective: To investigate the clinical efficacy and safety of fentokone in patients with incomplete abortion. Methods: From January 2011 to January 2014, the hospital was divided into two categories: one is FenTaoTong treatment group; the other is mifepristone plus oxytocin treatment group. Fifty cases were randomly selected from the Fentongtong group as the observation group, 50 cases from the mifepristone and oxytocin groups were taken as the control group, and the time of vaginal bleeding, Adverse drug reactions differences. Results: The observation group was superior to the control group in vaginal bleeding time, transit time and healing effect, but there was no significant difference in adverse drug reaction between the two groups. Conclusion: Fentoton treatment of incomplete (B-ultrasound abnormal uterine cavity echo maximum diameter <30mm), you can minimize re-curettage and promote uterine and menstrual recovery, it is worth promoting.